Opportunities
Search

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: УНИВЕРСИТЕТСКА МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ "СВ. ИВАН РИЛСКИ" ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: AB „Kelių priežiūra“ | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: Lesy České republiky, s.p. | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-11

Expected Impact:FOR ALL THREE THEMATIC PRIORITIES:Expected impact at the closure of the project (non-exhaustive list):Creation of new value chains in less developed regions and transition regions;Application and deployment of innovative technologies and solutions (new tothe region) in less developed and transition regions (innovation diffusion);Exploitation of project results;Innovative technologies tested and adopted by the market;Innovative solutions deployed improving businesses confidence, competencesand means to digitalise and grow;Contribution to digitisation and health systems transformation, through varioustypes of innovation and the supply of IT services;Uptake of technologically/economically reliable and viable solutions on themarket;Deployment of new technologies fostering the growth of Europe’s manufacturing sector;Innovative technologies adopted by SMEs;Identification of pos...

Expected Impact:FOR ALL THREE THEMATIC PRIORITIES:Expected impact at the closure of the project (non-exhaustive list): Innovative technologies tested and adopted by the market;Innovative solutions deployed improving businesses confidence, competences and means to digitalise and grow; Contribution to digitisation and health systems transformation, through various types of innovation and the supply of IT services;Uptake of technologically/economically reliable and viable solutions on the market;Deployment of new technologies fostering the growth of Europe’s manufacturing sector;Innovative technologies adopted by SMEs;Identification of possible sources of funding/funding mix, to cover the residual investment needs (public-private partnerships for the deployment of innovation, the collaboration with venture capitals, EIB group loans etc);Strengthening innovation diffusion channels;Reinforcin...

This program element does not have a proposal due date. Proposals may be submitted at any time, pending certain eligibility timing issues related to resubmissions and duplicate proposal avoidance, see the program element text and appropriate overview appendix (e.g., B.1 or C.1). The date shown of 8/1/2026 is the last day that proposals may be submitted subject to the ROSES-25 rules and the current GCAM. The ROSES-26 version of this program element is planned to overlap with this ROSES-25 version by a few weeks, allowing continuous submission of proposals across ROSES years. NOTICE: Updated July 21, 2026. The Anticipated Award Start Date for last submissions in Table C.2-1 in Section 3.1 has been updated. The requirements for Biographical Sketches and Current and Pending Support in Section 3.5 have been updated, as have the Expected program budget for first year of new awards and Number of new awards pending adequate proposals of merit in Section 6. New text is in bold and deleted text is struck through. NOTICE: Research security training required starting August 5, 2026. All PIs and any Co-Is that would spend ≥ 10% time on a proposed grants or cooperative agreements must certify they have taken research security training. NASA will be satisfied with the four online research security training modules on the National Science Foundation's (NSF) Research Security Training website at https://www.nsf.gov/research-security/training or the SECURE Center condensed version of the four modules at https://www.secure-center.org/ctm NOTICE: Amended July 2, 2026. Table C.2-1: Submission...

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Investigator-Initiated Research Award (IIRA) supports studies that have the potential to make an important contribution to spinal cord injury (SCI) research, patient care and/or quality of life. May focus on any phase of research from basic through translational science, though studies that focus solely on identifying intervention targets are discouraged.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two Principal Investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas.   Distinctive Features: ·       For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant Regulatory Agency by the CTA application submission deadline. In addition, applicants must provide documentation of communication from the Regulatory Agency indicating that the IND/IDE or equivalent is active/safe to proceed by March 1, 2027, in order for the CTA application to be considered for funding. Refer to Attachment 7: Regulatory Strategy for further details. ·       Scored peer review criteria include Clinical Impact; Research Strategy and Feasibility; Recruitment, Accrual, Retention; Regulatory Strategy and Transition Plan; Statistical Plan and Data Analysis; Ethical Considerations; Personnel and Communication. ·       Programmatic review criteria include adherence to the intent of the CTA, contribution to program portfolio, relative impact and relevance to military health. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of spinal cord injury (SCI).Distinctive Features: This funding opportunity contains an Early-Career Partnership Option, which allows for two Principal Investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the Initiating PI will submit a pre-application, but all PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.Applications to this funding opportunity must name at least two spinal cord injury (SCI) community partners (e.g., SCI Lived-Experience Consultants, representatives of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA) supports basic through early translational research that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction related to military exposure. The IIRA may be used to support preclinical studies and/or clinical research. Research must align with at least one of the FY26 VRP Focus Areas. The IIRA cannot be used to support clinical trials. Distinctive Features: ·        The IIRA offers two Funding Levels to support research at different stages and the exploration/development of ideas of different maturity levels. ·        Funding Level 2 includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI. ·        Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, and Personnel. ·        Programmatic review criteria include adherence to the intent of the IIRA, contribution to the VRP portfolio, relative impact, and relevance to military health. ·        The VRP may share FY26 IIRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Translational Research Award (TRA) supports translational research that transforms a promising discovery into new drugs, devices or clinical practice guidelines that are ready for definitive testing in clinical trials during or by the end of the period of performance. The TRA may be used to support preclinical studies, clinical research or a pilot clinical trial, but not a full-scale clinical trial. Research must align with at least one of the FY26 VRP Focus Areas. Distinctive Features: ·        If developing new drugs or device(s), the research team must include expertise in the regulatory approval process. ·        The TRA includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI. ·        Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, Personnel and Post-Award Transition Plan. ·        Programmatic review criteria include adherence to the intent of the TRA, contribution to the VRP portfolio, relative impact and relevance to military health. ·        The VRP may share FY26 TRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Translational Research Award (TRA) supports translational research that will accelerate the movement of promising ideas in spinal cord injury (SCI) research into clinical applications.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two principal investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.• Applications to this funding opportunity must name at least one SCI community partner (e.g., SCI Lived-Experience Consultant, representative of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Translation Research Award (CTRA) supports high-impact, new, or emerging clinical research that requires additional preliminary studies, such as feasibility, pilot, or optimization, to prepare for future larger-scale clinical trials or implementation. Primary objectives of this mechanism include:• Accelerating the translation of current and emerging techniques or interventions into clinical use by addressing specific barrier(s) to clinical success for the purpose of de-risking or informing the design of definitive trials.• Identifying the most effective diagnosis, treatment and rehabilitation options to support critical decision-making for patients, clinicians, care partners and policymakers.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two principal investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.• Applications to this funding opportunity must name at least two spinal cord injury (SCI) community partners who will provide advice and consultation throughout the planning and implementation of the research project.